Australia Biologics Safety Testing Market (2026-2031)
The Australia Biologics Safety Testing Market was valued at $40.7 Million in 2026 and projected to reach to $62.8 Million by 2031, representing a compound annual growth rate of 9.1%. Australia's biologics safety testing market is poised for sustained growth through 2031, supported by the country's robust regulatory framework and expanding biopharmaceutical innovation ecosystem.
Australia Biologics Safety Testing Market Trends and Insights
- This 9.1% compound annual growth rate reflects Australia's strengthening biopharmaceutical sector and increasing regulatory scrutiny around therapeutic biologics.
- Australia's position as a developed healthcare market with stringent safety standards drives demand for comprehensive testing services across contract research organizations and in-house laboratory facilities. The market expansion in Australia is underpinned by rising investment in biologic drug development, growing prevalence of chronic diseases requiring biologic therapies, and enhanced regulatory frameworks aligned with international standards.
- Australia's pharmaceutical companies and contract testing providers are scaling capabilities to meet both domestic and regional Asia-Pacific demand.
- Between 2026 and 2031, Australia's market is expected to capture increasing share of biologics safety testing services as local expertise and infrastructure mature..
Key Market Statistics
- CAGR (2026-2031) 9.1% CAGR
- Market Size, 2026 ~USD 40.7 Million
- Forecast, 2031 ~USD 62.8 Million
- Country Australia
Australia Biologics Safety Testing Market Overview
Market Valuation Growth :
Australia's biologics safety testing market is valued at $40.7 million in 2026, with projections reaching $62.8 million by 2031, representing a robust 9.1% CAGR driven by expanding biopharmaceutical development.
Regulatory Environment :
Australia's stringent TGA (Therapeutic Goods Administration) regulations and compliance requirements are accelerating demand for comprehensive safety testing services among local and international biopharmaceutical companies.
Biopharmaceutical Sector Expansion :
The strengthening Australian biopharmaceutical sector, supported by government initiatives and research funding, is driving increased investment in safety testing infrastructure and capabilities.
Regional Market Position :
As a developed healthcare market with advanced laboratory facilities and skilled workforce, Australia is becoming a preferred hub for biologics safety testing in the Asia-Pacific region.
Australia Biologics Safety Testing Market Dynamics
- The 9.1% CAGR reflects increasing demand from both domestic and international companies seeking TGA-compliant safety assessments for therapeutic biologics.
- Australia's position as a developed healthcare market with world-class research institutions and stringent safety standards continues to attract investment in testing capabilities. Key growth drivers include rising biologics development pipelines, heightened regulatory scrutiny, and Australia's strategic importance in Asia-Pacific drug development.
- The market will benefit from increased outsourcing of safety testing services, expansion of contract research organizations (CROs), and growing adoption of advanced testing methodologies.
- Government support for life sciences innovation further strengthens the market's trajectory toward $62.8 million by 2031..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Australia's biologics safety testing market is valued at $40.7 million in 2026 and will reach $62.8 million by 2031, representing a 9.1% CAGR.
- Australia's stringent regulatory environment and developed healthcare infrastructure drive consistent demand for advanced safety testing services.
- Australia's biopharmaceutical sector growth and regional Asia-Pacific expansion create opportunities for contract research organizations and testing providers.
- Australia's market growth is supported by increasing chronic disease prevalence and rising investment in biologic drug development through 2031.
Biologics Safety Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | STERILITY TESTING SERVICES (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 5.58 (2026) |
| Revenue Forecast (Billions) | ~USD 9.66 (2031) |
| Segments Covered | Offering, Type, Product & Service, Test Type, Application, End User |
Australia Biologics Safety Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioburden Testing Services
- Endotoxin Testing Services
- Mycoplasma Testing Services
- Other Biologics Safety Testing Services
- Other Bst Services
- Sterility Testing Services
- Virus Safety Testing Services
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Bioburden Tests
- Endotoxin Tests
- Mycoplasma Tests
- Other Biologics Safety Tests
- Residual Host Cell Proteins & Dna Detection Tests
- Sterility Tests
- Virus Safety Tests
By Application
- Blood & Blood Products Development And Manufacturing
- Cellular & Gene Therapy Products Development And Manufacturing
- Monoclonal Antibodies Development And Manufacturing
- Other Applications
- Vaccines Development And Manufacturing
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Companies : Domestic and international biopharmaceutical firms developing therapeutic biologics need Australia-specific market data to plan safety testing budgets, select CRO partners, and navigate TGA compliance requirements.
- Contract Research Organizations (CROs) : CROs operating in or entering Australia require detailed market sizing and growth forecasts to justify capacity investments, pricing strategies, and service expansion decisions in this developing market.
- Laboratory & Testing Service Providers : Safety testing laboratories and service providers need Australia market intelligence to identify growth opportunities, benchmark performance, and develop targeted marketing strategies for local clients.
- Healthcare Investors & Venture Capital : Investment firms evaluating opportunities in Australia's life sciences sector require credible market data to assess growth potential, competitive landscape, and return on investment for testing-related ventures.
- Regulatory & Compliance Consultants : Consultants advising biopharmaceutical clients on Australian market entry need localized market insights to provide informed guidance on testing requirements, timelines, and cost implications specific to Australia.
Key Companies in the Australia Biologics Safety Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (finished dosage manufacturing, packaging, lifecycle management),Pharmaceutical Development Services (formulation, clinical trial supply),Drug Substance Services (API and biologics substance), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Chemicals and Biochemicals Catalog,Cell Culture, Media, and Critical Raw Materials,Filtration, Labware, and Water Purification, |
| WUXI PHARMATECH (CAYMAN) INC | China | Private Company | Chemistry drug CRDMO services,Biology discovery and preclinical testing,Clinical research services, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, security, logistics, O&M), |
| AZELIS HOLDINGS SA | Belgium | Private Company | Coatings, Plastics & Advanced Materials Specialties,Food & Nutrition Ingredients,Personal Care & Home Care Ingredients, |
| CATALENT, INC. | United States | Private Company | Biologics (proteins, cell and gene, parenteral, large-molecule analytics),Pharma and Consumer Health – softgels and advanced oral dose (incl. Zydis),Pharma and Consumer Health – other oral, nasal, inhaled, topical, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
SIGMA-ALDRICH CORPORATION
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees specializing in life science and chemical products.
WUXI PHARMATECH (CAYMAN) INC
Wuxi Pharmatech (Cayman) Inc. is a China-based private company founded in 2000 with 8,837 employees providing pharmaceutical research and development services.
FLUOR CORPORATION
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees operating in engineering, procurement, and construction services.
AZELIS HOLDINGS SA
Azelis Holdings SA is a Belgium-based private company founded in 2001 with 1,325 employees specializing in specialty chemicals and ingredients.
CATALENT, INC.
Catalent, Inc. is a United States-based private company founded in 1933 with 16,900 employees offering pharmaceutical development and manufacturing services.
Reasons to Buy this Report
- Market-Specific Sizing & Forecasts : Access precise valuation data for Australia's biologics safety testing market with detailed 2026-2031 projections, enabling accurate budget allocation and investment planning specific to this developed healthcare economy.
- Regulatory Landscape Intelligence : Understand Australia's TGA requirements and compliance standards that drive demand for safety testing services, helping you tailor offerings and strategies to meet local regulatory expectations.
- Competitive Positioning Strategy : Identify growth opportunities within Australia's expanding biopharmaceutical sector and assess competitive dynamics to establish or strengthen your market presence in this high-value region.
- Investment & Expansion Planning : Leverage Australia-specific market insights to evaluate feasibility of establishing testing facilities, partnerships with local CROs, or expanding service capabilities in this growing market.
- Stakeholder Decision Support : Provide board members, investors, and executives with credible, localized market data to support strategic decisions regarding Australia operations and resource allocation.
Frequently asked questions
What is the current size of Australia's biologics safety testing market?
Australia's biologics safety testing market is valued at $40.7 million in 2026 and is projected to grow to $62.8 million by 2031.
What is the growth rate for biologics safety testing in Australia?
Australia's biologics safety testing market is growing at a compound annual growth rate (CAGR) of 9.1% from 2026 to 2031.
What factors are driving growth in Australia's biologics safety testing market?
Australia's market growth is driven by increased biopharmaceutical investment, stringent regulatory requirements, rising chronic disease prevalence, and expanding regional demand across Asia-Pacific.
Who are the key service providers in Australia's biologics safety testing market?
Australia's market includes contract research organizations, pharmaceutical companies with in-house testing capabilities, and specialized laboratory service providers serving domestic and regional clients.
How does Australia's market compare to the global biologics safety testing market?
Australia's 9.1% CAGR is slightly lower than the global 11.6% CAGR, reflecting Australia's mature market status within the broader Asia-Pacific region.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Biologics Safety Testing Market Report
Full forecast, segment splits, and company analysis for all Biologics Safety Testing Market.
- US Biologics Safety Testing Market
- Canada Biologics Safety Testing Market
- UK Biologics Safety Testing Market
- Germany Biologics Safety Testing Market
- France Biologics Safety Testing Market
- Italy Biologics Safety Testing Market
- Spain Biologics Safety Testing Market
- China Biologics Safety Testing Market
- Japan Biologics Safety Testing Market
- India Biologics Safety Testing Market
- South Korea Biologics Safety Testing Market
- Brazil Biologics Safety Testing Market
- Mexico Biologics Safety Testing Market
- Saudi Arabia Biologics Safety Testing Market
- UAE Biologics Safety Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report